Safety & Effectiveness of Delamanid-containing Regimen for MDR-TB Patients

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.

Clinical Trial Description

This is a single-arm, multicenter, phase #, open-label trial to evaluate the safety and effectiveness of delamanid-containing regimen in men and women aged 18 to 65 years with microbiologically confirmed pulmonary MDR-TB in China. A target of 600 participants will be enrolled. The study will consist of a screening phase of up to 8 weeks, an open-label study treatment phase of 13-20 months, and a follow-up phase of 12-month after end of study treatment. During the study treatment phase, participants will receive an MDR-TB regimen consisting of 24 weeks of delamanid in combination with 13-20 months of a background regimen. Participants will be instructed to take their assigned dose of delamanid with at least 3 additional probably effective background drugs according to national and international guidelines. Delamanid dosage will be 100 mg twice daily (b.i.d.) for 24 weeks. Safety evaluations will include monitoring of AEs, visual acuity testing, routine blood examinations (such as hematology, clinical chemistry, HIV, TSH [for subjects receiving PTO] measurements), urinalysis, and electrocardiograms (ECGs). Participants will initiate treatment with the study regimen if they meet the study eligibility criteria.The end of study will be considered as the last contact for the last participant in the study. A participant will be considered to have completed the study if he or she has completed the 13-20 months study treatment phase and the required post-treatment follow-up phase. Participants who prematurely discontinue study treatment (unless they withdraw consent) will be followed up for 12 months after end of delamanid treatment. ;

Study Design

Related Conditions & MeSH terms

Multidrug Resistant Tuberculosis
Tuberculosis
Tuberculosis, Multidrug-Resistant

Clinical Trial Details

NCT number	NCT04421495
Study type	Interventional
Source	Beijing Chest Hospital
Contact
Status	Active, not recruiting
Phase	Phase 4
Start date	July 16, 2020
Completion date	July 16, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05017324` - Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment Trial	N/A
Active, not recruiting	`NCT02496572` - Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan	Phase 3
Completed	`NCT03942354` - Patient-reported Experiences and Quality of Life Outcomes in the TB-PRACTECAL Clinical Trial
Completed	`NCT02454205` - An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis	Phase 2/Phase 3
Recruiting	`NCT05081401` - Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
Completed	`NCT01856634` - Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis	Phase 1
Active, not recruiting	`NCT03867136` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)	Phase 4
Not yet recruiting	`NCT04484129` - MDR-TB Close Contacts Tracing in China (TCCT Study)
Completed	`NCT00727844` - Linezolid to Treat Extensively-Drug Resistant Tuberculosis	Phase 2
Completed	`NCT01859923` - A 6-Month Safety, Efficacy, and Pharmacokinetic (PK) Trial of Delamanid in Pediatric Participants With Multidrug Resistant Tuberculosis (MDR-TB)	Phase 2
Active, not recruiting	`NCT04717908` - Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS	N/A
Not yet recruiting	`NCT03604848` - NGS-Guided(G) Regimens(R) of Anti-tuberculosis(A) Drugs for the Control(C) and Eradication(E) of MDR-TB	N/A
Recruiting	`NCT02120638` - Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide	Phase 3
Recruiting	`NCT05534750` - Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms